Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials

Bibliographic Details
Title: Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
Authors: Danese, Silvio *, Vermeire, Séverine, Zhou, Wen, Pangan, Aileen L, Siffledeen, Jesse, Greenbloom, Susan, Hébuterne, Xavier, D'Haens, Geert, Nakase, Hiroshi, Panés, Julian, Higgins, Peter D R, Juillerat, Pascal, Lindsay, James O, Loftus, Edward V, Jr, Sandborn, William J, Reinisch, Walter, Chen, Min-Hu, Sanchez Gonzalez, Yuri, Huang, Bidan, Xie, Wangang, Liu, John, Weinreich, Michael A, Panaccione, Remo
Source: In The Lancet 4-10 June 2022 399(10341):2113-2128
Database: ScienceDirect
More Details
ISSN:01406736
DOI:10.1016/S0140-6736(22)00581-5
Published in:The Lancet
Language:English